N-terminal RAG1 frameshift mutations in Omenn's syndrome:: Internal methionine usage leads to partial V(D)J recombination activity and reveals a fundamental role in vivo for the N-terminal domains

被引:59
作者
Santagata, S
Gomez, CA
Sobacchi, C
Bozzi, F
Abinun, M
Pasic, S
Cortes, P
Vezzoni, P
Villa, A
机构
[1] CNR, Ist Tecnol Biomed Avanzate, Dept Human Genome & Multifactorial Dis, I-20090 Segrate, MI, Italy
[2] CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA
[3] CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA
[4] Newcastle Gen Hosp, Childrens Bone Marrow Transplant Unit, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England
[5] Mother & Child Hlth Inst Serbia, Belgrade, Yugoslavia
关键词
D O I
10.1073/pnas.97.26.14572
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Omenn's syndrome is an autosomal recessive primary immunodeficiency characterized by variable numbers of T lymphocytes of limited clonality, hypereosinophilia, and high IgE levels with a paradoxical absence of circulating B lymphocytes. We have previously attributed this disorder to missense mutations that render the RAG1/RAG2 recombinase only partially active. Here we report seven Omenn's patients with a novel class of genetic lesions: frameshift mutations within the 5' coding region of RAG1. Interestingly, we demonstrate in transient expression experiments that these frameshift deletion alleles remain partially functional for both deletional and inversional recombination and can hence explain the partial rearrangement phenotype observed in these patients. The rearrangement activity is mediated by truncated RAG1 proteins that are generated by alternative ATG usage 3' to the frameshift deletion and that demonstrate improper cellular localization. Taken together, our results suggest a novel mechanism for the development of immunodeficiency in a subset of Omenn's syndrome patients.
引用
收藏
页码:14572 / 14577
页数:6
相关论文
共 41 条
[31]  
Shockett PE, 1999, MOL CELL BIOL, V19, P4159
[32]   Localization, interaction, and RNA binding properties of the V(D)J recombination-activating proteins RAG1 and RAG2 [J].
Spanopoulou, E ;
Cortes, P ;
Shih, C ;
Huang, CM ;
Silver, DP ;
Svec, P ;
Baltimore, D .
IMMUNITY, 1995, 3 (06) :715-726
[33]   The homeodomain region of Rag-1 reveals the parallel mechanisms of bacterial and V(D)J recombination [J].
Spanopoulou, E ;
Zaitseva, F ;
Wang, FH ;
Santagata, S ;
Baltimore, D ;
Panayotou, G .
CELL, 1996, 87 (02) :263-276
[34]  
Steen SB, 1996, GENES CELLS, V1, P543
[35]   SOMATIC GENERATION OF ANTIBODY DIVERSITY [J].
TONEGAWA, S .
NATURE, 1983, 302 (5909) :575-581
[36]   INITIATION OF V(D)J RECOMBINATION IN A CELL-FREE SYSTEM [J].
VANGENT, DC ;
MCBLANE, JF ;
RAMSDEN, DA ;
SADOFSKY, MJ ;
HESSE, JE ;
GELLERT, M .
CELL, 1995, 81 (06) :925-934
[37]   Omenn syndrome: A disorder of Rag1 and Rag2 genes [J].
Villa, A ;
Santagata, S ;
Bozzi, F ;
Imberti, L ;
Notarangelo, LD .
JOURNAL OF CLINICAL IMMUNOLOGY, 1999, 19 (02) :87-97
[38]   Partial V(D)J recombination activity leads to Omenn syndrome [J].
Villa, A ;
Santagata, S ;
Bozzi, F ;
Giliani, S ;
Frattini, A ;
Imberti, L ;
Gatta, LB ;
Ochs, HD ;
Schwarz, K ;
Notarangelo, LD ;
Vezzoni, P ;
Spanopoulou, E .
CELL, 1998, 93 (05) :885-896
[39]  
Wilson GM, 1999, GENOME RES, V9, P393
[40]   The SCFHOS/β-TRCP-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation [J].
Wu, K ;
Fuchs, SY ;
Chen, A ;
Tan, PL ;
Gomez, C ;
Ronai, Z ;
Pan, ZQ .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (04) :1382-1393